Eli Lilly updated the label for Trulicity, or dulaglutide, to demonstrate the efficacy and safety of the drug in adult patients with type 2 diabetes who have moderate to severe chronic kidney disease. In the AWARD-7 trial, patients achieved comparable glycemic control with weight loss when treated with Trulicity 1.5 mg or 0.75 mg in combination with mealtime insulin lispro, compared with the basal-bolus insulin group.
Eli Lilly adds diabetes drug label benefit data for adults with CKD
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.